瑞普生物(300119.SZ)：五种兽药产品获农业农村部批准

Core Viewpoint - Reap Bio (300119.SZ) has recently obtained a new veterinary drug registration certificate from the Ministry of Agriculture and Rural Affairs, indicating progress in its product development and regulatory approval process [1]. Group 1: New Drug Registration - Reap Bio's subsidiary, South China Agricultural University Biological Pharmaceutical Co., Ltd. (referred to as "South China Bio"), has successfully registered two diagnostic reagent products as veterinary drug products [1]. - The company has also received approval for two vaccine products, which have passed the production strain change review by the Ministry of Agriculture and Rural Affairs [1]. Group 2: Details of New Veterinary Drugs - The newly registered veterinary drugs include: - Recombinant Cat Interferon ω (lyophilized type) developed by Reap Bio and Zhongke Baike (Tianjin) Biological Pharmaceutical Co., Ltd. [2] - Avian Influenza Virus H7 subtype (rLN79 strain) developed by South China Agricultural University and other partners [2]. - Additionally, two inactivated vaccines for avian influenza have been applied for, including: - Bivalent inactivated vaccine for Avian Influenza Virus (H5N6 rHN503 strain + H5N1 rHN504 strain) [2]. - Quadrivalent inactivated vaccine for Avian Influenza Virus (H5N6 rHN503 strain + H5N1 rHN504 strain, H7N9 rHN705 strain + rHN706 strain) [2].